Henry S Friedman Selected Research

O(6)-benzylguanine

10/2009	Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
7/2009	Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
3/2009	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
2/2009	Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
11/2007	Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
3/2006	Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
10/2005	Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
9/2002	O6-benzylguanine-mediated enhancement of chemotherapy.
7/2002	Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
5/2002	Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Henry S Friedman Research Topics

Disease

107	Neoplasms (Cancer) 04/2022 - 01/2002
84	Glioma (Gliomas) 04/2022 - 01/2002
65	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 06/2002
36	Brain Neoplasms (Brain Tumor) 06/2021 - 01/2002
12	Melanoma (Melanoma, Malignant) 09/2011 - 01/2002
9	Fatigue 04/2022 - 10/2009
9	Medulloblastoma 01/2017 - 01/2002
8	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 01/2002
6	Hypoxia (Hypoxemia) 01/2014 - 01/2008
5	Chronic Disease (Chronic Diseases) 04/2022 - 12/2014
5	Vomiting 05/2020 - 03/2006
4	Nausea 05/2020 - 07/2014
4	Ependymoma 04/2015 - 01/2002
4	Infections 11/2014 - 05/2002
4	Central Nervous System Neoplasms 12/2013 - 05/2003
4	Diarrhea 07/2012 - 01/2004
3	Disease Progression 04/2019 - 01/2002
3	Lymphopenia (Lymphocytopenia) 01/2012 - 03/2011
3	Hemorrhage 01/2012 - 10/2009
3	Neutropenia 10/2009 - 01/2002
3	Rhabdomyosarcoma 11/2005 - 07/2002
3	Neuroblastoma 10/2004 - 09/2002
2	Poliomyelitis (Polio) 01/2021 - 11/2014
2	Lymphoma (Lymphomas) 04/2020 - 08/2013
2	Leukemia 09/2019 - 10/2003
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 12/2018 - 10/2009
2	Exanthema (Rash) 04/2015 - 12/2010
2	Headache (Headaches) 04/2015 - 03/2006
2	Meningioma (Meningiomas) 08/2012 - 01/2012
2	Carcinogenesis 09/2011 - 01/2011
2	Hypersensitivity (Allergy) 03/2011 - 11/2010

Drug/Important Bio-Agent (IBA)

44	Temozolomide (Temodar)FDA LinkGeneric 05/2020 - 09/2002
38	Bevacizumab (Avastin)FDA Link 04/2019 - 02/2007
30	Irinotecan (Camptosar)FDA LinkGeneric 04/2019 - 01/2002
22	ErbB Receptors (EGF Receptor)IBA 12/2014 - 01/2002
16	Monoclonal AntibodiesIBA 08/2012 - 03/2002
13	Proteins (Proteins, Gene)FDA Link 01/2019 - 08/2004
13	Pharmaceutical PreparationsIBA 01/2018 - 01/2002
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2014 - 09/2006
12	Carmustine (FIVB)FDA Link 08/2009 - 05/2002
11	epidermal growth factor receptor VIIIIBA 07/2018 - 01/2002
11	VaccinesIBA 01/2018 - 09/2003
10	Tyrosine Kinase InhibitorsIBA 07/2012 - 11/2002
10	O(6)-benzylguanineIBA 10/2009 - 05/2002
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2014 - 11/2005
7	EnzymesIBA 01/2019 - 09/2004
7	Alkylating AgentsIBA 08/2013 - 10/2002
7	Phosphotransferases (Kinase)IBA 06/2012 - 12/2004
6	Imatinib Mesylate (Gleevec)FDA Link 10/2012 - 12/2005
6	Peptides (Polypeptides)IBA 01/2012 - 01/2002
6	DNA (Deoxyribonucleic Acid)IBA 11/2010 - 09/2002
6	Alkyl and Aryl TransferasesIBA 02/2009 - 09/2002
5	7- chloro- 8- hydroxy- 1- (3'- iodophenyl)- 3- methyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepine (TISCH)IBA 06/2021 - 01/2007
5	AntigensIBA 01/2018 - 01/2002
5	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2012 - 12/2005
5	Melphalan (Alkeran)FDA LinkGeneric 05/2007 - 08/2004
4	AntiemeticsIBA 05/2020 - 07/2014
4	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2020 - 01/2018
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 06/2002
4	TOR Serine-Threonine KinasesIBA 10/2011 - 01/2005
4	O(6)-Methylguanine-DNA MethyltransferaseIBA 12/2009 - 05/2002
4	Topoisomerase I InhibitorsIBA 10/2006 - 04/2004
4	Gefitinib (Iressa)FDA Link 02/2006 - 11/2002
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 04/2015
3	MethyltransferasesIBA 01/2019 - 10/2005
3	Palonosetron (Aloxi)FDA Link 01/2017 - 07/2014
3	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 04/2006
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2012 - 11/2002
3	Carboplatin (JM8)FDA LinkGeneric 03/2012 - 07/2002
3	CytokinesIBA 01/2012 - 10/2002
3	Everolimus FDA Link 10/2011 - 01/2005
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2011 - 01/2005
3	Sirolimus (Rapamycin)FDA Link 01/2010 - 02/2006
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2010 - 02/2006
3	Immunotoxins (Immunotoxin)IBA 06/2008 - 01/2005
3	laromustine (VNP40101M)IBA 02/2008 - 01/2007
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2007 - 01/2002
3	Glutathione (Reduced Glutathione)IBA 05/2007 - 08/2004
2	Ondansetron (Zofran)FDA LinkGeneric 05/2020 - 01/2017
2	A-factor (Streptomyces)IBA 01/2019 - 01/2011
2	Vorinostat FDA Link 04/2018 - 01/2018
2	AcidsIBA 01/2018 - 11/2007
2	Messenger RNA (mRNA)IBA 01/2017 - 12/2014
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017 - 04/2015
2	RNA (Ribonucleic Acid)IBA 04/2015 - 03/2015
2	Mitogen-Activated Protein KinasesIBA 12/2014 - 09/2007
2	Carbonic Anhydrase IXIBA 01/2014 - 01/2008
2	AEE 788 (AEE788)IBA 06/2012 - 01/2005
2	Anticonvulsants (Antiepileptic Drugs)IBA 06/2012 - 02/2006
2	Tyrosine (L-Tyrosine)FDA Link 06/2012 - 06/2007
2	TransferasesIBA 12/2011 - 04/2006

Therapy/Procedure

68	Therapeutics 04/2022 - 01/2002
38	Drug Therapy (Chemotherapy) 04/2022 - 01/2002
26	Radiotherapy 04/2022 - 01/2002
8	Immunotherapy 01/2021 - 05/2008
5	Salvage Therapy 03/2012 - 04/2006
3	Catheters 12/2018 - 02/2007
3	Radioimmunotherapy 05/2007 - 09/2005
2	Oncolytic Virotherapy 03/2016 - 11/2014
2	Drug Tapering 04/2013 - 01/2002